DRTS
Alpha Tau Medical Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$13.23
−0.90%Oct 29, 2026, 16:14 UTC
Alpha Tau Medical announced that its ordinary shares will join the The Tel Aviv Stock Exchange Ltd.’s Alpha Tau Medical Ltd. and The Tel Aviv Stock Exchange Ltd. indices effective November 5, 2026.
Source:Oct 22, 2026, 12:31 UTC
Alpha Tau Medical Ltd. signed a memorandum of understanding with Samsung Medical Center.
Aug 31, 2026, 12:00 UTC
Alpha Tau Medical completed patient enrollment in its multicenter IMPACT pilot study of Alpha DaRT for unresectable pancreatic cancer, expanding enrollment from 12 to 48 patients.
Source:Jul 21, 2026, 12:30 UTC
Alpha Tau Medical reported positive clinical data for Alpha DaRT in combination with pembrolizumab in head and neck cancer at the AHNS conference on July 21, 2026.
Source:Jul 15, 2026, 12:30 UTC
Alpha Tau successfully treated the first immunocompromised patient with recurrent cutaneous squamous cell carcinoma in its ADMIRE study at Banner MD Anderson Cancer Center.
Source:Jun 3, 2026, 12:30 UTC
Alpha Tau Medical Ltd. and Tolmar International Ltd. announced a strategic collaboration to bring Alpha DaRT therapy to U.S. urological cancer patients, with Tolmar making an initial $15M manufacturing investment, a $20M equity infusion, and up to $161.5M in milestones.
Source: